Amicus Therapeutics Inc.'s bad preliminary news with Plicera from a small Phase II study in Gaucher disease "does advance the general proof of concept of chaperones" despite the failure, CEO John F. Crowley told investors during an aftermarket conference call Friday. (BioWorld Today) Read More